Biosergen AB announced a change in management from 31 January 2024 when Peder M. Andersen will step down from his current role as CEO and transition into a Chief Medical Officer role in Biosergen. The Board of Directors at Biosergen has appointed Tine Olesen as the new CEO from 1 February 2024 after serving as COO in Biosergen during the past two and half years. Peder M. Andersen has served as CEO of the company for the past six and a half years and will remain committed to the company in his new role and ensure a smooth transition.

Biosergen has evolved significantly under the leadership of Peder M. Andersen. Key highlights were the IPO in 2021, the first GMP-manufactured compound in 2019, Orphan Drug Designation in the USA for Aspergillosis in 2019, initiation of the project to nanoformulation of BSG005, completion of phase 1 in healthy volunteers in February, and final study report in May 2023, as well as the development and the licensing deal with Alkem September 2023. Tine Olesen, PhD., MBA, MSc.

has decades of experience from directing global, integrated development programs from early clinical stage to life cycle management primarily in the fields of oncology, neurology, inflammatory, and infectious diseases. Her responsibilities have included design and execution of novel strategies from early (first in man) stage through marketing authorization and market access with key focus on CMC, clinical development, and regulatory interactions. This has led to global regulatory approvals of New Drug Applications and Biologics License Applications in the EU, Japan, and the USA.

In addition, she has served as Vice President of a development organisation of biosimilars. She has been active in the interpretation of key scientific data, building value propositions, and developing new businesses. Finally, she has been a member of the Board of Directors for Pharma15 Corp.

that was acquired by Radiopharm Theranostics.